KR102686835B1 - 티오펜 유도체의 결정형 - Google Patents

티오펜 유도체의 결정형 Download PDF

Info

Publication number
KR102686835B1
KR102686835B1 KR1020207033658A KR20207033658A KR102686835B1 KR 102686835 B1 KR102686835 B1 KR 102686835B1 KR 1020207033658 A KR1020207033658 A KR 1020207033658A KR 20207033658 A KR20207033658 A KR 20207033658A KR 102686835 B1 KR102686835 B1 KR 102686835B1
Authority
KR
South Korea
Prior art keywords
ethyl
thieno
ethoxy
methoxyphenyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207033658A
Other languages
English (en)
Korean (ko)
Other versions
KR20210025000A (ko
Inventor
동레이 장
리유 왕
유군 창
Original Assignee
톈진 헤메이 파마슈티칼 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 톈진 헤메이 파마슈티칼 컴퍼니 리미티드 filed Critical 톈진 헤메이 파마슈티칼 컴퍼니 리미티드
Publication of KR20210025000A publication Critical patent/KR20210025000A/ko
Application granted granted Critical
Publication of KR102686835B1 publication Critical patent/KR102686835B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
KR1020207033658A 2018-05-02 2019-04-30 티오펜 유도체의 결정형 Active KR102686835B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810407741 2018-05-02
CN201810407741.X 2018-05-02
PCT/CN2019/085342 WO2019210865A1 (zh) 2018-05-02 2019-04-30 噻吩衍生物的晶型

Publications (2)

Publication Number Publication Date
KR20210025000A KR20210025000A (ko) 2021-03-08
KR102686835B1 true KR102686835B1 (ko) 2024-07-22

Family

ID=68386284

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207033658A Active KR102686835B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207033791A Active KR102701245B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207034757A Active KR102839924B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207034790A Ceased KR20210022557A (ko) 2018-05-02 2019-04-30 티오펜 유도체의 고체 형태

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207033791A Active KR102701245B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207034757A Active KR102839924B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207034790A Ceased KR20210022557A (ko) 2018-05-02 2019-04-30 티오펜 유도체의 고체 형태

Country Status (14)

Country Link
US (4) US11396518B2 (cg-RX-API-DMAC10.html)
EP (5) EP3800190A4 (cg-RX-API-DMAC10.html)
JP (5) JP7481263B2 (cg-RX-API-DMAC10.html)
KR (4) KR102686835B1 (cg-RX-API-DMAC10.html)
CN (7) CN116947878B (cg-RX-API-DMAC10.html)
AU (4) AU2019262282B2 (cg-RX-API-DMAC10.html)
BR (4) BR112020021976A2 (cg-RX-API-DMAC10.html)
CA (4) CA3213055A1 (cg-RX-API-DMAC10.html)
DK (1) DK3789389T3 (cg-RX-API-DMAC10.html)
ES (1) ES3047059T3 (cg-RX-API-DMAC10.html)
FI (1) FI3789389T3 (cg-RX-API-DMAC10.html)
PL (1) PL3789389T3 (cg-RX-API-DMAC10.html)
PT (1) PT3789389T (cg-RX-API-DMAC10.html)
WO (4) WO2019210869A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3789389T3 (pl) * 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101186612A (zh) 2006-11-15 2008-05-28 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
CN101885731A (zh) * 2009-05-14 2010-11-17 天津和美生物技术有限公司 噻吩衍生物
WO2018231604A1 (en) 2017-06-13 2018-12-20 Biotheryx, Inc. Bicyclic compounds and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
US8946474B2 (en) * 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2016010178A1 (ko) * 2014-07-18 2016-01-21 주식회사 녹십자 5-클로로-n-({(5s)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
EP3644860B1 (en) * 2017-06-30 2024-05-08 Trophy An extra oral dental imaging apparatus with patient positioning accessory detection
PL3789389T3 (pl) 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101186612A (zh) 2006-11-15 2008-05-28 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
CN101885731A (zh) * 2009-05-14 2010-11-17 天津和美生物技术有限公司 噻吩衍生物
WO2018231604A1 (en) 2017-06-13 2018-12-20 Biotheryx, Inc. Bicyclic compounds and methods of use

Also Published As

Publication number Publication date
EP4335515A2 (en) 2024-03-13
US11396518B2 (en) 2022-07-26
DK3789389T3 (da) 2025-11-10
AU2019263865B2 (en) 2022-01-27
JP2024026251A (ja) 2024-02-28
FI3789389T3 (fi) 2025-11-19
JP2021523935A (ja) 2021-09-09
JP2021523891A (ja) 2021-09-09
KR20210025001A (ko) 2021-03-08
EP3789388B1 (en) 2024-01-24
JP7542523B2 (ja) 2024-08-30
AU2019262282A1 (en) 2020-11-12
EP3800190A4 (en) 2022-01-26
KR20210022557A (ko) 2021-03-03
CA3098927C (en) 2023-10-03
PT3789389T (pt) 2025-12-17
CA3099072A1 (en) 2019-11-07
KR102701245B1 (ko) 2024-08-30
EP3789387B1 (en) 2024-02-28
WO2019210864A1 (zh) 2019-11-07
ES3047059T3 (en) 2025-12-03
JP2021523890A (ja) 2021-09-09
BR112020022190A2 (pt) 2021-02-02
EP3789389A4 (en) 2022-01-26
EP3800190A1 (en) 2021-04-07
CN110437251B (zh) 2023-07-21
US12180222B2 (en) 2024-12-31
CN116854705A (zh) 2023-10-10
CA3098931C (en) 2023-10-24
EP3789389A1 (en) 2021-03-10
PL3789389T3 (pl) 2026-03-16
CA3099071A1 (en) 2019-11-07
US20210380600A1 (en) 2021-12-09
US20210139498A1 (en) 2021-05-13
CN116836178A (zh) 2023-10-03
EP3789387A4 (en) 2021-06-30
BR112020021945A2 (pt) 2021-01-26
WO2019210869A1 (zh) 2019-11-07
BR112020021976A2 (pt) 2021-01-26
JP7481263B2 (ja) 2024-05-10
US12227514B2 (en) 2025-02-18
WO2019210865A1 (zh) 2019-11-07
EP4335515A3 (en) 2024-07-03
JP7477459B2 (ja) 2024-05-01
KR20210022556A (ko) 2021-03-03
AU2019262286B2 (en) 2022-08-11
JP2021522348A (ja) 2021-08-30
US20210230181A1 (en) 2021-07-29
EP3789388A4 (en) 2021-06-09
CA3098931A1 (en) 2019-11-07
WO2019210867A1 (zh) 2019-11-07
AU2019263865A1 (en) 2020-12-24
CN110437250B (zh) 2023-06-23
CN110437249B (zh) 2023-07-21
US20210238191A1 (en) 2021-08-05
CN116947878A (zh) 2023-10-27
CN116854705B (zh) 2026-06-19
CN116947878B (zh) 2026-06-19
KR20210025000A (ko) 2021-03-08
EP3789388A1 (en) 2021-03-10
US11274104B2 (en) 2022-03-15
EP3789389B1 (en) 2025-10-08
CN116813637A (zh) 2023-09-29
CN110437251A (zh) 2019-11-12
AU2019262282B2 (en) 2022-04-28
AU2019262284A1 (en) 2020-12-24
CA3098927A1 (en) 2019-11-07
KR102839924B1 (ko) 2025-07-29
EP3789387A1 (en) 2021-03-10
CN110437250A (zh) 2019-11-12
CA3213055A1 (en) 2019-11-07
CN110437249A (zh) 2019-11-12
BR112020022186A2 (pt) 2021-02-02
AU2019262286A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
KR102701245B1 (ko) 티오펜 유도체의 결정형
CA3099071C (en) Crystal forms of thiophene derivatives
HK40047648B (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048512B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047648A (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048511A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048512A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048511B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047649A (en) Solid form of thiophene derivative

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201123

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201123

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221018

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230712

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240111

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240704

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240716

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240717

End annual number: 3

Start annual number: 1

PG1601 Publication of registration